The group now has 102 approvals
Zydus Cadila has received approval from the United States Food and Drug Administration (US FDA) to market Doxycycline Capsules USP, 50 mg, 75 mg, and 100 mg. The drug falls in the anti-bacterials segment.
With this first approval, the group will now commence supplies to the US market from its formulation manufacturing facility located at the SEZ in Ahmedabad.
The group now has 102 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-04.